Double-staging fused lncRNA (long non-coding ribonucleic acid) selection method
A dual, clinical staging technology, applied in the field of lncRNA selection, can solve the problems of time-consuming, neglected disease dual staging data association, and inability to give diseases, and achieve the effect of improving the global optimization ability.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0074] (1) 480 lncRNA transcripts of prostate cancer patients were obtained in the lncRNAtor database, and the dual-stage DS data was obtained from the clinical data of prostate cancer patients in the TCGA database. A total of 118 effective clinical stage CT data and 174 effective PT data of pathological staging. The lncRNA data matrix M that will be used for clinical stage prediction CTP (contains 104 clinical stage available data) and lncRNA data matrix M for pathological stage prediction LC (Contains 170 available data of pathological stages) After taking the intersection, correlate the dual staging matrix DSM (contains 101 available data of dual staging), and finally obtains the lncRNA data matrix M for dual staging prediction DS .
[0075] (2) Use the DSSCA algorithm (where wei is set to 0.6) to calculate M respectively DS Medium 480 Lr i The importance of D-significance(Lr i ), according to D-significance (Lr i ) will Lr i Constructed as a linear descending queue ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


